Although combination therapy of radiation and antibody to cell surface GRP78 has demonstrated promise in in vitro and in mouse xenograft models, Akt/mTOR pathway inhibitors have yet to demonstrate meaningful benefit in GBM clinical trials (46). Here, HSPA5 is linked to glioblastoma.